Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.

Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy

Open access

Abstract

Calcific aortic valve disease (CAVD) is a highly prevalent condition that comprises a disease continuum, ranging from microscopic changes to profound fibro-calcific leaflet remodelling, culminating in aortic stenosis, heart failure, and ultimately premature death. Traditional risk factors, such as hypercholesterolaemia and (systolic) hypertension, are shared among atherosclerotic cardiovascular disease and CAVD, yet the molecular and cellular mechanisms differ markedly. Statin-induced low-density lipoprotein cholesterol lowering, a remedy highly effective for secondary prevention of atherosclerotic cardiovascular disease, consistently failed to impact CAVD progression or to improve patient outcomes. However, recently completed phase II trials provide hope that pharmaceutical tactics directed at other targets implicated in CAVD pathogenesis offer an avenue to alter the course of the disease non-invasively. Herein, we delineate key players of CAVD pathobiology, outline mechanisms that entail compromised endothelial barrier function, and promote lipid homing, immune-cell infiltration, and deranged phospho-calcium metabolism that collectively perpetuate a pro-inflammatory/pro-osteogenic milieu in which valvular interstitial cells increasingly adopt myofibro-/osteoblast-like properties, thereby fostering fibro-calcific leaflet remodelling and eventually resulting in left ventricular outflow obstruction. We provide a glimpse into the most promising targets on the horizon, including lipoprotein(a), mineral-binding matrix Gla protein, soluble guanylate cyclase, dipeptidyl peptidase-4 as well as candidates involved in regulating phospho-calcium metabolism and valvular angiotensin II synthesis and ultimately discuss their potential for a future therapy of this insidious disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab757

Cites

214 of 214 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 214 references

Cited by

See all 281

Metadata

Authors
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F.
Affiliations
  • University of Zurich (CH)
  • Brigham and Women's Hospital (US)
Corresponding author
Lüscher, Thomas F
Venue
European Heart Journal
Published
2021-11-25
Volume
43
Issue
7
Pages
683-697
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3215076242
Cited by
281
References
214
Citations by year
2026: 59 · 2025: 78 · 2024: 81 · 2023: 35 · 2022: 28
FWCI
24.27
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Swiss Heart Foundation (FF20094)
  • Foundation of Cardiovascular Research—Zurich Heart House
  • National Institutes of Health (R01HL136431, R01HL141917, R01HL147095)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
calcific aortic valve disease, aortic stenosis, valve calcification, endothelial barrier dysfunction, immune cell infiltration, valvular interstitial cells, osteoblast-like differentiation, left ventricular outflow tract obstruction, lipoprotein(a), matrix Gla protein, soluble guanylate cyclase, dipeptidyl peptidase IV, angiotensin II, statins, atherosclerosis, inflammation, therapeutic target
MeSH terms
Aortic Valve, Aortic Valve Stenosis, Calcinosis, Cells, Cultured, Humans, Osteogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. https://app.cochat.ai/papers/10.1093/eurheartj/ehab757
The paper
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022). Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab757

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.